Latest Tax Incentives News

Barton Gold Holdings has secured a $520,000 cash refund through the Federal Government’s R&D Tax Incentive, bolstering its exploration efforts in South Australia’s emerging gold province.

Sparc Technologies has secured a $680,000 non-dilutive advance on its anticipated FY26 R&D tax refund, strengthening its cash flow as it accelerates commercialisation of its graphene additive ecosparc and green hydrogen ventures.

Advanced Energy Minerals is ramping up production capacity at its Quebec plant, leveraging patented low-cost technology and renewable energy to meet booming global demand for high purity alumina.

Argenica Therapeutics has secured a nearly $4 million R&D tax incentive rebate for FY25, strengthening its cash position as it prepares for a pivotal Phase 2b trial of its neuroprotective peptide ARG-007.

Resonance Health has received a $732,851 refund from the Australian Taxation Office, reflecting its FY2025 R&D tax incentive claim net of income tax payable. This cash inflow strengthens the company’s financial position ahead of its March quarterly report.

Elixir Energy has completed drilling the Lorelle-3H well in Queensland’s Taroom Trough, achieving over 1,000 metres of high-quality net gas-condensate pay and setting a new benchmark for lateral drilling in the basin. A multi-stage fracture stimulation and production test is planned for Q2 2026, potentially paving the way for Elixir’s first reserves booking.

Acrux Limited has secured a $0.55 million advance on its FY26 R&D Tax Incentive, providing crucial funding to accelerate development of its Hormone Replacement Therapy following FDA regulatory confirmation.

Janus Electric has locked in a $2.75 million R&D finance facility, strengthening its cash position to push forward with its zero-emission transport innovations. This strategic funding avoids shareholder dilution while supporting ongoing technology development.

Entropy Neurodynamics has received a $1.73 million R&D tax incentive refund from the Australian Government, reinforcing its clinical development of an intravenous psilocin treatment for neuropsychiatric disorders.

AuMEGA Metals has announced a C$5.35 million capital raising via a flow-through unit offer aimed at advancing its exploration projects in Newfoundland and Labrador. The offer includes shares and warrants, targeting Canadian charity investors with tax incentives.

Chimeric Therapeutics has secured a $1.785 million advance against its anticipated FY26 Research and Development Tax Incentive to bolster its clinical trial pipeline and working capital.

Galan Lithium’s Hombre Muerto West project in Argentina is 92% through Phase 1 construction, with commissioning and first lithium chloride concentrate production expected in 2026.